Iovance Biotherapeutics, Inc.
Iovance is a patient-centric, collaborative organization that is driven to change the way cancer is treated.
925 employees · est. 2007 · San Carlos, United States
Lyell Immunopharma
At Lyell, we are advancing next-generation CAR T-cell product candidates for patients with cancer.
229 employees · est. 2018 · South San Francisco, United...
Iovance Biotherapeutics, Inc. is the older company (2007 vs 2018); Iovance Biotherapeutics, Inc. is the larger of the two.
Side-by-Side Comparison
| Metric | Iovance Biotherapeutics, Inc. | Lyell Immunopharma |
|---|---|---|
| Founded | ||
| Founded | 2007 older | 2018 |
| Headquarters | ||
| Headquarters | San Carlos, United States | South San Francisco, United States |
| Employees | ||
| Employees | 925 larger | 229 |
| Industry | ||
| Industry | Biotechnology, Health Care | Biotechnology |
| Funding Stage | ||
| Funding Stage | IPO | Unknown |
| Total Funding | ||
| Total Funding | $1.78B | $968.00M |
| Funding Rounds | ||
| Funding Rounds | 10 | 6 |
| Services | ||
| Services | TIL Therapy Development, Clinical Research, Manufacturing at Cell Therapy Center, Scientific Publications & Presentations, Pipeline Development for Advanced Solid Tumor Cancers | Development of Next-Generation CAR T-Cell Product Candidates, Cancer Cell Killing Capabilities, Clinical-Stage Research and Development, Advanced Manufacturing and Supply Chain Management, Cancer Target Identification |
| Target Customers | ||
| Target Customers | Patients with Advanced Solid Tumor Cancers, Healthcare Providers, Clinical Researchers, Pharmaceutical Investors | Cancer Patients, Healthcare Providers, Medical Researchers, Oncologists, Healthcare Institutions |
| Taxonomy | ||
| Taxonomy | Patient-Centric Organization, Cancer Treatment Innovation, Tumor Infiltrating Lymphocytes (TIL) Therapy, Autologous T-Cell Treatment, Immunotherapy Development, Solid Tumor Focus, Gene-Edited Cell Therapy, Cell Therapy Manufacturing, Clinical Data Development, Regulatory Approval Preparation, San Francisco Bay Area Headquarters, Philadelphia Manufacturing Facility, Tampa Research Site, Commercial Launch Execution, Cancer Immunotherapy Commercialization | CAR T-cell Therapies, Cancer Treatment, Cell Therapy, Clinical Stage Biotechnology, T-cell Biology, Immunotherapy, Stemness Technology, Tumor Cytotoxicity, Biopharmaceutical Research, Cell Manufacturing, Oncology Therapies, Novel Technology Development, Clinical Evaluation, Integrated Biotech Company, Next-generation Treatments |
| Website | ||
| Website | iovance.com | lyell.com |
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a biotechnology company founded in 2007 with a mission to revolutionize cancer treatment through its innovative tumor infiltrating lymphocyte (TIL) therapies. As a patient-centric organization, Iovance harnesses the human immune system's potential to target and elimi...
About Lyell Immunopharma
Lyell Immunopharma, a United States-based biotechnology firm, is pioneering the development of next-generation CAR T-cell therapies aimed at cancer treatment. Founded in 2018 by cell therapy pioneers, the company leverages cutting-edge technology to enhance T cells with characteristics of resistance...
We will tell you when either one moves
BounceWatch watches Iovance Biotherapeutics, Inc. and Lyell Immunopharma for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Iovance Biotherapeutic... and Lyell Immunopharma — by email.
Frequently Asked Questions
Compare Iovance Biotherapeutics, Inc. with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Iovance Biotherapeutics, Inc. on 9 Jun 2026, and Lyell Immunopharma on 16 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
